AbCellera Biologics Inc.
ABCL Nasdaq
SEC CIK 1703057
Follow AbCellera Biologics
Weekly email: filings, results
Revenue, last quarter
$10.6M
+18.8% vs same quarter last year
Net income
−$40.8M
+28.6% vs same quarter last year
EPS, diluted
−$0.13
+31.6% vs same quarter last year
Operating cash flow
$26.9M
+151.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $75.1M | −$146.4M |
| FY24 | $28.8M | −$162.9M |
| FY23 | $38M | −$146.4M |
| FY22 | $485.4M | $158.5M |
| FY21 | $375.2M | $153.5M |
| FY20 | $233.2M | $118.9M |
| FY19 | $11.6M | −$2.2M |
| FY18 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −289% | −194.9% |
| FY24 | −1091.7% | −564.8% |
| FY23 | −623.8% | −385% |
| FY22 | 44.6% | 32.7% |
| FY21 | 54.5% | 40.9% |
| FY20 | 66.9% | 51% |
| FY19 | −35.5% | −19% |
| FY18 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$174.1M |
| FY24 | −$187M |
| FY23 | −$120.8M |
| FY22 | $206.7M |
| FY21 | $186.1M |
| FY20 | $13M |
| FY19 | −$1.3M |
| FY18 | - |
- AbCellera Biologics
- Healthcare median
Show the numbers
| Year | AbCellera Biologics | Healthcare median |
|---|---|---|
| FY25 | −194.9% | −30.6% |
| FY24 | −564.8% | −47% |
| FY23 | −385% | −58% |
| FY22 | 32.7% | −80.4% |
| FY21 | 40.9% | −71.9% |
| FY20 | 51% | −62.2% |
| FY19 | −19% | −46.3% |
| FY18 | - | −49.6% |